These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19285266)

  • 21. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.
    Pertwee RG
    Curr Med Chem; 2010; 17(14):1360-81. PubMed ID: 20166927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 23. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
    Bramlage P; Böcking W; Kirch W
    Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA; Johnson JC
    Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
    Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
    Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys.
    Madsen MV; Peacock L; Werge T; Andersen MB
    J Psychopharmacol; 2006 Sep; 20(5):622-8. PubMed ID: 16533866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
    Immenschuh S
    Cardiovasc Res; 2009 Dec; 84(3):341-2. PubMed ID: 19819883
    [No Abstract]   [Full Text] [Related]  

  • 29. CB1 cannabinoid receptor-mediated modulation of food intake in mice.
    Wiley JL; Burston JJ; Leggett DC; Alekseeva OO; Razdan RK; Mahadevan A; Martin BR
    Br J Pharmacol; 2005 Jun; 145(3):293-300. PubMed ID: 15778743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An introduction to the endocannabinoid system: from the early to the latest concepts.
    De Petrocellis L; Di Marzo V
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):1-15. PubMed ID: 19285257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoid-1 receptor antagonists in type-2 diabetes.
    Scheen AJ
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors.
    Ottani A; Leone S; Sandrini M; Ferrari A; Bertolini A
    Eur J Pharmacol; 2006 Feb; 531(1-3):280-1. PubMed ID: 16438952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cannabis and cannabinoids as drugs].
    Khiabani HZ; Mørland J
    Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
    Horder J; Browning M; Di Simplicio M; Cowen PJ; Harmer CJ
    J Psychopharmacol; 2012 Jan; 26(1):125-32. PubMed ID: 21406493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
    Lastres-Becker I; Bizat N; Boyer F; Hantraye P; Brouillet E; Fernández-Ruiz J
    Neuroreport; 2003 May; 14(6):813-6. PubMed ID: 12858038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial comes too late as psychiatric side effects end hope for rimonabant.
    Stapleton JA
    Addiction; 2009 Feb; 104(2):277-8. PubMed ID: 19149824
    [No Abstract]   [Full Text] [Related]  

  • 39. Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
    Pertwee RG
    Br J Pharmacol; 2009 Feb; 156(3):397-411. PubMed ID: 19226257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depression-like phenotype following chronic CB1 receptor antagonism.
    Beyer CE; Dwyer JM; Piesla MJ; Platt BJ; Shen R; Rahman Z; Chan K; Manners MT; Samad TA; Kennedy JD; Bingham B; Whiteside GT
    Neurobiol Dis; 2010 Aug; 39(2):148-55. PubMed ID: 20381618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.